This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition

Bridger Management sold its entire Masimo stake, liquidating 47,841 shares and reducing the quarter-end position value by $7.06M. Masimo shares were at $178.24 (market cap ~$9.6B) and shortly after the sale the company agreed to an acquisition at $180/share (~$9.9B), which drove a roughly 34% one-time jump in the stock. The fund’s portfolio remains concentrated in large-cap, cash-generating names (e.g., MS, AMZN) suggesting a tilt toward stability at the expense of event-driven upside. For investors, the move highlights timing risk around event-driven catalysts (M&A) despite otherwise mixed company fundamentals (TTM revenue ~$1.5B, TTM net loss $207.7M).

Analysis

A liquidation by an active manager like Bridger is more a sizing and mandate signal than a verdict on fundamentals; funds tilted to large-cap, cash-generating names will trim mid‑cap, event‑driven positions to reduce VaR and correlation noise. That dynamic mechanically widens spreads and increases the cost of capital for small-to-mid cap names that live off episodic M&A or strategic interest, which in turn invites private equity and strategic bidders who can pay control premiums and extract distribution synergies.

For the underlying business, consolidation risk is the key second‑order effect: an acquirer can immediately compress SG&A and accelerate OEM/recurring revenue rollout across channel partners, while component suppliers and niche OEM partners face single‑buyer concentration risk. Hospitals’ capex cyclicality and reimbursement uncertainty are the primary valuation knobs acquirers will use; any deterioration in hospital budgets can both delay synergies and give buyers leverage to renegotiate economics during diligence.

Catalyst timeline is short‑to‑intermediate: deal certainty typically resolves in 1–9 months via due diligence, financing and regulatory checks, so volatility will cluster around those windows. Tail risks — deal termination, competing bidder dynamics, regulatory objections — can inflict 20–40% downside versus a capped upside for financed deals, which argues for defined‑risk exposure rather than naked directional stakes.

Portfolio implication: selling into a drawdown is often the rational choice for managers constrained by concentration limits, but it also trims optionality that creates asymmetric returns. For us, the right response is to selectively re‑establish M&A optionality using option structures sized small relative to NAV while redeploying core capital into durable, cash‑generative large caps to stabilize portfolio carry and liquidity.

Key Decisions for Investors

• Event‑arb (defined risk) — MASI: initiate a 1–2% NAV married‑put position (buy MASI equity + buy 6‑month put ~25–30% OTM). Timeframe 3–6 months. Rationale: preserves upside from deal/strategic outcomes while capping downside to roughly put cost + equity loss; expected reward conditional on deal resolution ~+15–30%, max downside limited.
• Tail optionality (cheap premium) — MASI: buy a 3‑month call spread (buy near‑ATM or 10% OTM, sell 40% OTM) sized 0.5–1% NAV. Timeframe 1–3 months. Rationale: low cash outlay to capture deal announcement move; max loss = premium, target asymmetric payoff ~2–3x if a bidder/announcement appears.
• Redeploy into platform growth — AMZN: buy a 9–12 month call spread (buy 10% OTM, sell 40% OTM) sizing 1–2% NAV. Timeframe 9–12 months. Rationale: move capital from binary event risk to durable AI/commerce optionality with limited premium outlay; risk = premium (~1–2% NAV), upside capped by spread but offers 2–4x return if thesis plays out.
• Defensive ballast — MS: increase position by 1% NAV (cash equity or synthetic long) as portfolio shock absorber. Timeframe 6–12 months. Rationale: fee revenue, buybacks and lower beta provide drawdown mitigation while optionality positions run; risk: macro‑driven AUM compression could pressure shares ~10–20% in severe market stress.